YCCI’s 4th Annual All Scholar Day Retreat is slated for Thursday, October 6, in the Mary S. Harkness Auditorium, Sterling Hall of Medicine, 333 Cedar Street. This half-day event is open to all students, trainees, scholars, and faculty at Yale who are participating or interested in clinical or translational research.
This year, we are very pleased that Robert M. Califf, MD, MACC, Commissioner, Food and Drug Administration (FDA), and Petra Kaufmann, MD, MSc, Clinical Innovation Director, National Center for Advancing Translational Sciences (NCATS), NIH, will be speaking.
An internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Robert Califf, MD, MACC, has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature. As the leader of the FDA since February, 2016, Dr. Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health. Previously, Dr. Califf served as the FDA’s deputy commissioner for Medical Products and Tobacco. He also oversaw the Office of Special Medical Programs and provided direction for cross-cutting clinical, scientific, and regulatory initiatives, including precision medicine, combination products, orphan drugs, pediatric therapeutics, and the advisory committee system. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. At Duke, Dr. Califf led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative, a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke’s Clinical and Translational Science Award.
NCATS Clinical Investigation Director Petra Kaufmann, MD, MSc, leads the Clinical and Translational Science Awards (CTSA) program with the aim of improving the effectiveness and efficiency of the process of translation from scientific discovery through clinical research to improved health outcomes. She is also the director of NCATS’s Office of Rare Diseases Research, and oversees NCATS’ Rare Diseases Clinical Research Network, Genetic and Rare Diseases Information Center, and the NIH/NCATS Global Rare Diseases Patient Registry Data Repository/GRDR® program. Before joining NCATS, Kaufmann was the director of the Office of Clinical Research at the National Institute of Neurological Disorders and Stroke, where she worked with investigators to plan and execute a large portfolio of clinical research studies and trials in neurological disorders, including many in rare diseases. She established NeuroNEXT, a trial network for Phase II trials using a central institutional review board, streamlined contracting, active patient participation in all project phases, and a scientific and legal framework for partnership with industry. Kaufmann also promoted data sharing, working with multiple stakeholders from the academic, patient organization and industry sectors to develop data standards for more than ten neurological diseases.
Breakfast begins at 7 a.m., followed by an introduction of Dr. Califf by Dean of the School of Medicine, Robert Alpern. MD at 7:40 a.m. Dr. Califf will present until 8:30 a.m., followed by oral presentations of five abstracts from 8:30 to 10:00 a.m. Dr. Kaufmann will speak at 10 a.m. with closing remarks from YCCI Director Robert Sherwin, MD at 11:00 a.m. Lunch and a poster session will be held from 11:15 to 1 p.m.
For more information or to register visit the webpage here.